Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II observer-blind randomized placebo-controlled study of an HSV-targeted immunotherapy in healthy adults and adults with recurrent genital herpes
2024-510571-37-00Phase 2Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, randomised, single-blind trial of GSKVX000000030825 and GSK208141 + non-MPL-containing adjuvant in herpes simplex (HSV) and genital herpes (2 arms), sponsored by GSK. Started May 2024; status: completed.
02
Drugs
GSKVX000000030825GSK208141 + non-MPL-containing adjuvant
03
Conditions
herpes simplex (HSV)genital herpes
Beyond the preview
Go deeper on 2024-510571-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510571-37-00.